Latest Distribution Channels News

Beam Communications reported a robust Q1FY26 with revenue doubling quarter-on-quarter and cash reserves more than doubling, yet ongoing arbitration over its Zoleo divestment casts a shadow on its capital return plans.

BrainChip Holdings has moved its AKD1500 neuromorphic AI chip into volume production, supported by key supply agreements and expanded distribution channels, while maintaining a stable cash position.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

MyState Limited’s merger with Auswide Bank has driven a 17% rise in underlying net profit to $41.3 million for FY25, alongside a strengthened capital position and a fully franked 11 cent dividend.

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

Halo Technologies has appointed Peter Oxlade as CEO and George Paxton as COO, aligning leadership with its recent $3.9 million capital raise to fuel expansion across the Asia-Pacific region.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.